Navigation Links
Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting
Date:5/11/2010

PARIS, May 11 /PRNewswire-FirstCall/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, announces today that Frederic Paques, PhD, Chief Scientific Officer, has been invited to present Cellectis' approaches on vectors for meganucleases and genome surgery at the 13th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting to be held at the Marriott Wardman Park Hotel in Washington, USA, on May 19-22, 2010.

Targeted approaches have emerged today as an alternative to current random insertion strategies for gene therapy. Meganucleases, the most specific endonucleases, represent ideal tools for targeted genome editing, or genome surgery. They can induce up to 20% of gene insertion into chosen human genes. The entry of meganucleases into different cell types can be achieved by various means, including viral and non-viral vectorization.

Dr Paques will discuss "Meganucleases and Viral Vectors: Alternative or Complementary Approaches" on May 22, 2010, at 8:30AM, during an oral session on Special Considerations with Using Viral Vectors for Gene Modification of Stem Cells.

About Cellectis

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools - meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.

To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.

Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over EUR 70 million in funding since inception.

More information at www.cellectis.com

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.


'/>"/>
SOURCE Cellectis
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology
2. Cellectis and Regeneron Sign an Agreement Over the use of Homologous Recombination Technology
3. Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology
4. Zymes LLC, University of Windsor and National Research Council of Canada Collaborative Research Presented at the 2010 Experimental Biology Meeting in Anaheim, California
5. BioMed Realty Trust to Webcast Company Presentation at Investor Day 2010
6. Dyadic International to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference
7. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
8. Yongye International to Present at Upcoming Investor Conferences
9. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
10. Talecris Biotherapeutics to Present at the Bank of America Merrill Lynch Health Care Conference
11. Brazilian Biotechnology Present at BIO 2010 Is Looking for the Worldwide Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... In starting a program to hire college athletes, ... for attitude. Train for skill.” , In keeping with this philosophy, the Catalyst an ... salesman. Zamzow is hoping to replicate the practice throughout the company. , “I’ve heard ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... (TDR) procedures can be safely completed in an ambulatory surgery center (ASC) with ... (ACDF) procedures and previous two-year TDR studies. , Jake Lubinski, president of ...
(Date:2/24/2017)... DIEGO , Feb. 24, 2017  Aethlon Medical, ... following note authored by its Chairman and CEO, ... at the Munich Security Conference last Saturday, Bill ... virus could kill more people than nuclear weapons. Mr. ... U.S. and U.K. intelligence agencies, that scientific terrorists have ...
(Date:2/24/2017)... ... 24, 2017 , ... FireflySci, Inc is an explosive small business that continues ... goal of bringing their powerful cuvette and spectrophotometer calibration to the spectroscopy ... is going on as they add yet another mark on the global map. , ...
Breaking Biology Technology:
(Date:2/16/2017)... Feb. 16, 2017  Genos, a community for ... it has received Laboratory Accreditation from the College ... presented to laboratories that meet stringent requirements around ... rigorous processes. "Genos is committed to ... practices. We,re honored to be receiving CAP accreditation," ...
(Date:2/13/2017)... WASHINGTON , Feb. 13, 2017 Former ... U.S. Senate Judiciary Committee, Janice Kephart of ... regarding President Donald Trump,s "Executive Order: Protecting ... States" (Jan. 27, 2017):  "As President Trump,s ... 9th Circuit has now essentially banned the travel ban, ...
(Date:2/8/2017)... NEW YORK , Feb. 8, 2017 /PRNewswire/ ... an individual,s voice to match it against a ... voice such as pitch, cadence, and tone are ... systems require minimal hardware installation, as most PCs ... remotely for different transactions. Voice recognition biometrics are ...
Breaking Biology News(10 mins):